Lei Li

Company snapshot

Lei Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Recurrent Cervical Carcinoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lei Li. Not investment advice.

• What is Lei Li?

  Lei Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Recurrent Cervical Carcinoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sour

• Is Lei Li publicly traded?

  Lei Li appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Lei Li develop or market?

  We link 3 drug profile(s) where Lei Li is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lei-li#company-drugs.

• What are the latest developments for Lei Li?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lei Li focus on?

  Lei Li focuses on Recurrent Cervical Carcinoma based on our analysis of their pipeline programs and drug development activities.